HomeNewsBusinessBanks yet again look at NBFC lending as credit demand is back, asset quality improves

Banks yet again look at NBFC lending as credit demand is back, asset quality improves

Banks’ credit to NBFCs rose by 30.6% year on year to Rs 11.7 lakh crore in September 2022, mainly due to a favourable base effect, the RBI data shows. This is nearly double the overall credit growth in the system

November 15, 2022 / 14:02 IST
Story continues below Advertisement

Banks’ outstanding credit to non-banking financial companies (NBFCs) has risen on the back of high demand for credit, stabilising asset quality trends and improving collection efficiency, bankers and industry experts have told Moneycontrol.

Banks’ credit to NBFCs rose by 30.6 percent year on year (YoY) to Rs 11.7 lakh crore in September 2022, mainly due to a favourable base effect, according to Reserve Bank of India (RBI) data.

Story continues below Advertisement

This is nearly double the overall credit growth in the system. In absolute terms, bank credit to NBFCs increased by Rs 2.74 lakh crore over the last year and by Rs 93,000 crore from March 2022.

A favourable base effect is one where the comparative number for the base period, in this case September 2021, is unusually low, which leads to the percentage growth in the current period being large in comparison.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show